Verrica Pharmaceuticals has announced the acceptance of a late-breaking abstract detailing Phase 2 exploratory data for VP-315, a novel oncolytic peptide aimed at treating basal cell carcinoma (BCC). This data will be presented at the upcoming 2026 Society for Investigative Dermatology Annual Meeting in Chicago. The study, titled “VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma Tumors,” highlights the peptide’s potential to induce immunogenic cell death, thereby eliciting a broad T cell response against tumors.

The significance of these findings lies in VP-315’s mechanism as a first-in-class oncolytic chemotherapeutic immunotherapy. Administered directly into tumors, it aims to provide a non-surgical treatment option for patients with BCC, a condition that currently sees 3.6 million diagnoses annually in the U.S. and is often treated through invasive surgical methods. The Phase 1/2 trials have already demonstrated promising tumor-specific immune responses, suggesting that VP-315 could address the high unmet need for effective, less invasive treatments for skin cancers.

The implications of this research are substantial for the field of dermatological oncology. If VP-315 continues to show efficacy in larger trials, it could shift the treatment paradigm for non-melanoma skin cancers, potentially reducing reliance on surgical interventions and associated complications. This development may also accelerate the timeline for drug development in this area, as it opens avenues for further exploration of oncolytic peptides in cancer therapy, potentially leading to more innovative treatment strategies for various skin malignancies.

Source: globenewswire.com